High prevalence of lipopolysaccharide mutants and R2-pyocin susceptible variants in populations sourced from cystic fibrosis lung infections.

Cystic fibrosis (CF) patients often experience chronic, debilitating lung infections caused by antibiotic-resistant , contributing to antimicrobial resistance (AMR). The genetic and phenotypic diversity of populations in CF lungs raises questions about their susceptibility to non-traditional antimicrobials, like bacteriocins. In this study, we focused on R-pyocins, a type of bacteriocin with high potency and a narrow killing spectrum.

High prevalence of lipopolysaccharide mutants and R2-Pyocin susceptible variants in populations sourced from cystic fibrosis lung infections.

Chronic, highly antibiotic-resistant infections in cystic fibrosis (CF) lungs contribute to increasing morbidity and mortality. , a common CF pathogen, exhibits resistance to multiple antibiotics, contributing to antimicrobial resistance (AMR). These bacterial populations display genetic and phenotypic diversity, but it is unclear how this diversity affects susceptibility to bacteriocins.